Antibodies to TNFα
View Patent ↗Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNFα); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.
1. An isolated antibody or antigen binding portion capable of binding TNF-α, wherein:
the V H antibody chain comprises SEQ ID NO:20, excluding sequences identified by SEQ ID NO: 40; and
the V L (variable light chain) antibody chain comprises at least one of the V L CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 49, 50 and 51, respectively.
2. An isolated antibody or antigen binding portion capable of binding TNF-α, wherein:
the V L antibody chain comprises SEQ ID NO:27, excluding the sequence identified by SEQ ID NO: 42; and
the V H (variable heavy chain) antibody chain comprises at least one of the V H CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 43, 44, and 45, respectively.
3. A pharmaceutical composition, comprising an isolated antibody or antigen binding portion thereof capable of binding TNF-α wherein:
the V L (variable light chain) antibody chain comprises at least one of the V L CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 49, 50 and 51; and
wherein the V H antibody chain comprises SEQ ID NO:291,
excluding an isolated antibody or antigen binding portion thereof capable of binding TNF-α which comprises a V H antibody chain comprising at least one of the V H CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 46, 47, and 48 respectively and which comprises a V L antibody chain comprising at least one of the V L CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 52, 53 and 54, respectively.
4. A pharmaceutical composition, comprising an isolated antibody or antigen binding portion thereof capable of binding TNF-α, wherein the V L antibody chain comprises SEQ ID NO:292; and the V H (variable heavy chain) antibody chain comprises at least one of the V H CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 43, 44, and 45.
5. The pharmaceutical composition of claim 4 , wherein the V H antibody chain comprises SEQ ID NO:291.
6. An isolated antibody or antigen binding portion of the isolated antibody, wherein:
the V L (variable light chain) antibody chain comprises at least one of the V L CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 49, 50 and 51; and
the V H antibody chain comprises SEQ ID NO:291,
excluding an isolated antibody or antigen binding portion thereof capable of binding TNF-α which comprises a V H antibody chain comprising at least one of the V H CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 46, 47, and 48 respectively and which comprises a V L antibody chain comprising at least one of the V L CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 52, 53 and 54, respectively.
7. An isolated antibody or antigen binding portion of the isolated antibody, wherein:
the V H (variable heavy chain) antibody chain comprises at least one of the V H CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 43, 44, and 45, respectively; and
the V L antibody chain comprises SEQ ID NO:292.
8. The isolated antibody or antigen binding portion of the isolated antibody of claim 7 , wherein the V H antibody chain comprises SEQ ID NO:291.
9. The isolated antibody or antigen binding portion thereof of claim 2 , wherein the V H antibody chain comprises SEQ ID NO:20, excluding sequences identified by SEQ ID NO: 40.
10. A pharmaceutical composition comprising an isolated antibody or antigen binding portion capable of binding TNF-α, wherein:
the V H antibody chain comprises SEQ ID NO:20, excluding sequences identified by SEQ ID NO: 40; and
the V L (variable light chain) antibody chain comprises at least one of the V L CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 49, 50 and 51, respectively.
11. A pharmaceutical composition comprising an isolated antibody or antigen binding portion capable of binding TNF-α, wherein:
the V L antibody chain comprises SEQ ID NO:27, excluding the sequence identified by SEQ ID NO: 42; and
the V H (variable heavy chain) antibody chain comprises at least one of the V H CDR1, CDR2 and CDR3 regions whose sequences are identified by SEQ ID NO: 43, 44, and 45, respectively.
12. The pharmaceutical composition of claim 11 , wherein the V H antibody chain comprises SEQ ID NO:20, excluding sequences identified by SEQ ID NO: 40.